Deep Cuts? 2023 sales to decline by as much as 33% compared with record-breaking 2022













Not sure what you are talking about. Eliquis patent goes unti early 2027. And we all know pfizer will sell it to the end before they fire us. Vyndamax gone early 2025. They go first. Nothing to replace it. Thoughts?
 




I think we have been moving away from primary care for awhile now. All the $$$ going to specialty company purchases for their pipelines and in-house R&D is focused in the specialty care, rare disease and oncology BUs.
 




I think we have been moving away from primary care for awhile now. All the $$$ going to specialty company purchases for their pipelines and in-house R&D is focused in the specialty care, rare disease and oncology BUs.

Except Pfizer recently purchased Biohaven for their migraine franchise of products whose growth and full potential will be driven by primary care. There is big revenue in primary care and will continue to be.
 




































It’s clear rhe Biohaven reps are much better than the rest. You will be replaced for people that actually WORK

move over

Hahahahaha yeah okay. Cuts coming by EOY once the nasal spray flops and eats into nurtec sales since that flopped as a prevention(the head to head with emgality is going to show nurtec as an embarrassment)